Abstract: The potential mechanism of isobavachalcone in tr ulcerative colitis (UC) treat-ment was explored using network pharmacology, Gene Expression Omnibus (GEO) se-quencing data, and molecular docking. Isobavachalcone targets were obtained from Pub-Chem and other databases. Disease targets of UC were obtained from GeneCards, Dis-GeNET, and the GEO database. The intersection of two data sets was used to obtain isobavachalcone targets for UC. The core targets were screened by constructing the in-tersection gene protein interaction network, and the binding activity between drugs and core targets was preliminarily verified using molecular docking. In total, 107 drug and disease intersection genes were obtained. Enrichment analysis was predominantly related to inflammation. Core targets AKT1, MMP9, EGFR, IGF1, and SRC were obtained by screening. Good binding activity between isobavachalcone and core targets was confirmed by molecular docking simulation. Accordingly, the therapeutic role of isobavachalcone in UC may be mediated via the regulation of inflammation-related signaling pathways by acting on core targets, providing data support for subsequent in-depth studies.

Key words: network pharmacology, GEO database, isobavachalcone, ulcerative colitis